RxDoctor Payments Data

Syed Ali, MD

Interventional Cardiology · Oklahoma City, OKNPI 1760612014

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $13,669 of the $19,207 with a category attached, or 71.2%. 18 manufacturers reported payments, led by Edwards Lifesciences at 42.8% of the total. 2025 is the largest year on record at $7,624, more than ten times the $110 reported in 2019.

$19,207in general payments, 2019–2025

Across 168 payments — averaging $114.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$8K
  • Abbott$4K
  • Boston Scientific$3K
  • Medtronic$3K
  • Penumbra, Inc.$1K
  • Abiomed$389
  • plus $369 from 12 others

What the payments were for

  • Travel & lodging$13,66971%
  • Food & beverage$5,53729%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,207 in reported general payments places this provider in the 75th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$105,735
Medicare patients
420
Services billed
1,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$156,432
EntrestoSacubitril/Valsartan78$72,090
XareltoRivaroxaban30$19,331
VascepaIcosapent Ethyl27$12,005
BrilintaTicagrelor12$11,726
FarxigaDapagliflozin Propanediol11$8,703
Atorvastatin Calcium591$7,313
Repatha PushtronexEvolocumab11$7,174
Torsemide150$6,546
Prasugrel Hcl67$6,108
Telmisartan123$5,871
Potassium Chloride326$5,075
Ranolazine ErRanolazine41$3,195
Amlodipine Besylate369$2,966
Metoprolol Succinate200$2,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$156,432171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →